Compare Lennar Corporation (LEN) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

LEN trades at $77.60, up 1.93% today, but faces a bearish technical outlook with recent earnings misses and declining profitability. Revenue fell to $34.19B in 2025 with net income margin dropping to 6.07%, while valuation ratios like P/E of 14.7 and P/B of 0.86 suggest potential undervaluation. Berkshire Hathaway's increased stake to 11.2% contrasts with analyst caution, as the stock hovers near support at $76 amid weak housing market sentiment.

The stock presents a value opportunity given low P/B and P/S ratios, but risks include persistent earnings underperformance, high mortgage rates pressuring housing demand, and allegations in a short report. Analyst consensus is mixed with a $77.38 price target, implying limited upside, while institutional buying by Berkshire signals long-term confidence amid near-term headwinds.

DENTSPLY SIRONA (XRAY) trades at $8.69, down 1.76% on the day and near a 52-week low, reflecting ongoing operational challenges. The stock shows a bearish technical trend with weak moving averages, while fundamentals reveal declining revenue, negative net income margins, and elevated debt levels. Recent Q2 2026 earnings beat expectations but sales fell 4.1%, indicating persistent headwinds in dental markets.

The outlook remains cautious due to margin pressure and competitive threats, though analyst consensus suggests upside to a $13.40 price target. Key risks include execution of the turnaround plan, macroeconomic sensitivity, and high leverage. Investment appeal hinges on successful restructuring and recovery in core dental segments.